Management of immune-related adverse events in endocrine organs induced by immune checkpoint inhibitors: clinical guidelines of the Japan Endocrine Society
-
- Arima Hiroshi
- Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan
-
- Iwama Shintaro
- Department of Endocrinology and Diabetes, Nagoya University Hospital, Nagoya 466-8560, Japan
-
- Inaba Hidefumi
- The First Department of Medicine, Wakayama Medical University, Wakayama 641-8509, Japan
-
- Ariyasu Hiroyuki
- The First Department of Medicine, Wakayama Medical University, Wakayama 641-8509, Japan
-
- Makita Noriko
- Division of Nephrology and Endocrinology, University of Tokyo Graduate School of Medicine, Tokyo 113-8655, Japan
-
- Otsuki Michio
- Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Suita 565-0871, Japan
-
- Kageyama Kazunori
- Department of Endocrinology and Metabolism, Hirosaki University Graduate School of Medicine, Hirosaki 036-8562, Japan
-
- Imagawa Akihisa
- Department of Internal Medicine (I), Osaka Medical College, Takatsuki 569-8686, Japan
-
- Akamizu Takashi
- The First Department of Medicine, Wakayama Medical University, Wakayama 641-8509, Japan
Search this article
Description
<p>Immune checkpoint inhibitors (ICIs) have become a promising treatment for advanced malignancies. However, these drugs can induce immune-related adverse events (irAEs) in several organs, including skin, gastrointestinal tract, liver, muscle, nerve, and endocrine organs. Endocrine irAEs comprise hypopituitarism, primary adrenal insufficiency, thyroid dysfunction, hypoparathyroidism, and type 1 diabetes mellitus. These conditions have the potential to lead to life-threatening consequences, such as adrenal crisis, thyroid storm, severe hypocalcemia, and diabetic ketoacidosis. It is therefore important that both endocrinologists and oncologists understand the clinical features of each endocrine irAE to manage them appropriately. This opinion paper provides the guidelines of the Japan Endocrine Society and in part the Japan Diabetes Society for the management of endocrine irAEs induced by ICIs.</p>
Journal
-
- Endocrine Journal
-
Endocrine Journal 66 (7), 581-586, 2019
The Japan Endocrine Society